AP883A - Synthetic IL-10 analogues. - Google Patents

Synthetic IL-10 analogues. Download PDF

Info

Publication number: AP883A
Authority: AP; ARIPO
Prior art keywords: polypeptide; amino acid; thr; arg; lys
Prior art date: 1996-01-18

Application number

APAP/P/1998/001295A

Other languages

English (en)

Other versions

AP9801295A0 (en

Inventor

Christian Gronhoj Larsen

Borbala Gesser

Original Assignee

Steeno Res Group A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-18

Filing date

1997-01-16

Publication date

2000-10-25

1997-01-16 Application filed by Steeno Res Group A/S filed Critical Steeno Res Group A/S

1998-09-30 Publication of AP9801295A0 publication Critical patent/AP9801295A0/xx

2000-10-25 Application granted granted Critical

2000-10-25 Publication of AP883A publication Critical patent/AP883A/en

Links

108090000174 Interleukin-10 Proteins 0.000 title description 74
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 208
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 113
150000001413 amino acids Chemical class 0.000 claims abstract description 96
239000000126 substance Substances 0.000 claims abstract description 80
125000000539 amino acid group Chemical group 0.000 claims abstract description 37
206010033645 Pancreatitis Diseases 0.000 claims abstract description 30
238000011282 treatment Methods 0.000 claims abstract description 28
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
239000000816 peptidomimetic Substances 0.000 claims abstract description 16
238000011321 prophylaxis Methods 0.000 claims abstract description 13
238000002360 preparation method Methods 0.000 claims abstract description 10
208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 6
208000011580 syndromic disease Diseases 0.000 claims abstract description 6
229920001184 polypeptide Polymers 0.000 claims description 86
238000004519 manufacturing process Methods 0.000 claims description 69
210000001616 monocyte Anatomy 0.000 claims description 61
210000001744 T-lymphocyte Anatomy 0.000 claims description 59
108090001007 Interleukin-8 Proteins 0.000 claims description 47
230000000694 effects Effects 0.000 claims description 38
238000000034 method Methods 0.000 claims description 30
230000035605 chemotaxis Effects 0.000 claims description 26
230000014509 gene expression Effects 0.000 claims description 26
230000021995 interleukin-8 production Effects 0.000 claims description 25
241000283973 Oryctolagus cuniculus Species 0.000 claims description 23
102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 21
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 21
108010074328 Interferon-gamma Proteins 0.000 claims description 20
102000004169 proteins and genes Human genes 0.000 claims description 20
108090000623 proteins and genes Proteins 0.000 claims description 20
102100037850 Interferon gamma Human genes 0.000 claims description 19
108090000978 Interleukin-4 Proteins 0.000 claims description 19
206010033647 Pancreatitis acute Diseases 0.000 claims description 19
201000003229 acute pancreatitis Diseases 0.000 claims description 19
230000005764 inhibitory process Effects 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 16
206010061218 Inflammation Diseases 0.000 claims description 14
230000004054 inflammatory process Effects 0.000 claims description 14
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 13
230000003399 chemotactic effect Effects 0.000 claims description 13
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 12
125000003275 alpha amino acid group Chemical group 0.000 claims description 12
239000003613 bile acid Substances 0.000 claims description 12
210000000265 leukocyte Anatomy 0.000 claims description 12
101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 11
101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 10
108700012920 TNF Proteins 0.000 claims description 10
230000002269 spontaneous effect Effects 0.000 claims description 10
230000001684 chronic effect Effects 0.000 claims description 9
210000004072 lung Anatomy 0.000 claims description 9
238000000338 in vitro Methods 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
230000005012 migration Effects 0.000 claims description 8
238000013508 migration Methods 0.000 claims description 8
101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 7
102000019223 Interleukin-1 receptor Human genes 0.000 claims description 7
230000003247 decreasing effect Effects 0.000 claims description 7
230000001419 dependent effect Effects 0.000 claims description 7
108050006617 Interleukin-1 receptor Proteins 0.000 claims description 6
206010053879 Sepsis syndrome Diseases 0.000 claims description 6
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 6
230000008595 infiltration Effects 0.000 claims description 6
238000001764 infiltration Methods 0.000 claims description 6
238000011555 rabbit model Methods 0.000 claims description 6
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
206010009900 Colitis ulcerative Diseases 0.000 claims description 5
230000001965 increasing effect Effects 0.000 claims description 5
210000000440 neutrophil Anatomy 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
206010016654 Fibrosis Diseases 0.000 claims description 4
201000005569 Gout Diseases 0.000 claims description 4
102000004551 Interleukin-10 Receptors Human genes 0.000 claims description 4
108010017550 Interleukin-10 Receptors Proteins 0.000 claims description 4
206010027476 Metastases Diseases 0.000 claims description 4
230000003042 antagnostic effect Effects 0.000 claims description 4
230000004761 fibrosis Effects 0.000 claims description 4
208000024908 graft versus host disease Diseases 0.000 claims description 4
230000002458 infectious effect Effects 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
239000002502 liposome Substances 0.000 claims description 4
230000009401 metastasis Effects 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
206010003210 Arteriosclerosis Diseases 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
210000004185 liver Anatomy 0.000 claims description 3
210000004698 lymphocyte Anatomy 0.000 claims description 3
230000001613 neoplastic effect Effects 0.000 claims description 3
230000010410 reperfusion Effects 0.000 claims description 3
201000000306 sarcoidosis Diseases 0.000 claims description 3
239000007790 solid phase Substances 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
201000004384 Alopecia Diseases 0.000 claims description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
201000003874 Common Variable Immunodeficiency Diseases 0.000 claims description 2
241000701022 Cytomegalovirus Species 0.000 claims description 2
206010018364 Glomerulonephritis Diseases 0.000 claims description 2
206010020843 Hyperthermia Diseases 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
208000009388 Job Syndrome Diseases 0.000 claims description 2
208000016604 Lyme disease Diseases 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
206010035664 Pneumonia Diseases 0.000 claims description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
206010042953 Systemic sclerosis Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
231100000360 alopecia Toxicity 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
210000003719 b-lymphocyte Anatomy 0.000 claims description 2
230000008878 coupling Effects 0.000 claims description 2
238000010168 coupling process Methods 0.000 claims description 2
238000005859 coupling reaction Methods 0.000 claims description 2
201000002491 encephalomyelitis Diseases 0.000 claims description 2
208000010227 enterocolitis Diseases 0.000 claims description 2
230000033687 granuloma formation Effects 0.000 claims description 2
206010051040 hyper-IgE syndrome Diseases 0.000 claims description 2
230000036031 hyperthermia Effects 0.000 claims description 2
239000000367 immunologic factor Substances 0.000 claims description 2
238000009169 immunotherapy Methods 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
210000000056 organ Anatomy 0.000 claims description 2
238000010647 peptide synthesis reaction Methods 0.000 claims description 2
208000028169 periodontal disease Diseases 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
150000003839 salts Chemical group 0.000 claims description 2
239000012453 solvate Substances 0.000 claims description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
102000003777 Interleukin-1 beta Human genes 0.000 claims 1
108090000193 Interleukin-1 beta Proteins 0.000 claims 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
206010000210 abortion Diseases 0.000 claims 1
231100000176 abortion Toxicity 0.000 claims 1
230000002862 amidating effect Effects 0.000 claims 1
230000000087 stabilizing effect Effects 0.000 claims 1
230000002194 synthesizing effect Effects 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 23
230000009467 reduction Effects 0.000 abstract description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 7
230000009385 viral infection Effects 0.000 abstract description 5
208000036142 Viral infection Diseases 0.000 abstract description 2
230000006433 tumor necrosis factor production Effects 0.000 abstract description 2
GTORPNRZTBKYJB-AIEIIIEWSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]hexanoyl Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 GTORPNRZTBKYJB-AIEIIIEWSA-N 0.000 description 138
108010034537 alanyl-tyrosyl-methionyl-threonyl-methionyl-lysyl-isoleucyl-arginyl-asparagine Proteins 0.000 description 137
102100039068 Interleukin-10 Human genes 0.000 description 73
229940076144 interleukin-10 Drugs 0.000 description 73
229940024606 amino acid Drugs 0.000 description 72
210000004027 cell Anatomy 0.000 description 62
102000004890 Interleukin-8 Human genes 0.000 description 46
102000000589 Interleukin-1 Human genes 0.000 description 30
108010002352 Interleukin-1 Proteins 0.000 description 30
108060008682 Tumor Necrosis Factor Proteins 0.000 description 24
230000006698 induction Effects 0.000 description 21
102000004127 Cytokines Human genes 0.000 description 20
108090000695 Cytokines Proteins 0.000 description 20
239000002158 endotoxin Substances 0.000 description 19
102000004388 Interleukin-4 Human genes 0.000 description 18
239000000203 mixture Substances 0.000 description 18
229920006008 lipopolysaccharide Polymers 0.000 description 17
239000000556 agonist Substances 0.000 description 16
238000002474 experimental method Methods 0.000 description 16
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 16
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 15
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 15
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 14
108091003079 Bovine Serum Albumin Proteins 0.000 description 14
241000699670 Mus sp. Species 0.000 description 14
-1 superoxide anions Chemical class 0.000 description 14
230000001225 therapeutic effect Effects 0.000 description 14
239000012894 fetal calf serum Substances 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
241001529936 Murinae Species 0.000 description 12
KDGBLMDAPJTQIW-RHYQMDGZSA-N Thr-Met-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N)O KDGBLMDAPJTQIW-RHYQMDGZSA-N 0.000 description 12
XKXAZPSREVUCRT-BPNCWPANSA-N Ala-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 XKXAZPSREVUCRT-BPNCWPANSA-N 0.000 description 11
239000012981 Hank's balanced salt solution Substances 0.000 description 11
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 11
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 11
239000000427 antigen Substances 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
102100021277 Beta-secretase 2 Human genes 0.000 description 10
101710150190 Beta-secretase 2 Proteins 0.000 description 10
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
239000012980 RPMI-1640 medium Substances 0.000 description 9
102100040247 Tumor necrosis factor Human genes 0.000 description 9
238000003556 assay Methods 0.000 description 9
238000011534 incubation Methods 0.000 description 9
210000005087 mononuclear cell Anatomy 0.000 description 9
230000001629 suppression Effects 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
201000002364 leukopenia Diseases 0.000 description 8
231100001022 leukopenia Toxicity 0.000 description 8
229940044551 receptor antagonist Drugs 0.000 description 8
239000002464 receptor antagonist Substances 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
102000006354 HLA-DR Antigens Human genes 0.000 description 7
108010058597 HLA-DR Antigens Proteins 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000009471 action Effects 0.000 description 6
206010003246 arthritis Diseases 0.000 description 6
239000006071 cream Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000004033 plastic Substances 0.000 description 6
229920003023 plastic Polymers 0.000 description 6
239000003380 propellant Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000004044 response Effects 0.000 description 6
238000007363 ring formation reaction Methods 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000283707 Capra Species 0.000 description 5
102000019034 Chemokines Human genes 0.000 description 5
108010012236 Chemokines Proteins 0.000 description 5
102000001189 Cyclic Peptides Human genes 0.000 description 5
108010069514 Cyclic Peptides Proteins 0.000 description 5
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
230000004913 activation Effects 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 5
201000010153 skin papilloma Diseases 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000001262 western blot Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 4
102000000646 Interleukin-3 Human genes 0.000 description 4
108010002386 Interleukin-3 Proteins 0.000 description 4
241000282898 Sus scrofa Species 0.000 description 4
208000000260 Warts Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000004075 alteration Effects 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
102000052620 human IL10 Human genes 0.000 description 4
230000017307 interleukin-4 production Effects 0.000 description 4
230000011268 leukocyte chemotaxis Effects 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000028550 monocyte chemotaxis Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000004043 responsiveness Effects 0.000 description 4
230000035939 shock Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
238000008157 ELISA kit Methods 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
229930182566 Gentamicin Natural products 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000009809 T cell chemotaxis Effects 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
101710090398 Viral interleukin-10 homolog Proteins 0.000 description 3
239000002253 acid Chemical group 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000011324 bead Substances 0.000 description 3
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000002975 chemoattractant Substances 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
238000000586 desensitisation Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000004417 polycarbonate Substances 0.000 description 3
230000036515 potency Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
RNHKOQHGYMTHFR-UBHSHLNASA-N Ala-Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 RNHKOQHGYMTHFR-UBHSHLNASA-N 0.000 description 2
240000003291 Armoracia rusticana Species 0.000 description 2
208000006386 Bone Resorption Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
208000037273 Pathologic Processes Diseases 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
108010077895 Sarcosine Proteins 0.000 description 2
MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000024279 bone resorption Effects 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
108010017391 lysylvaline Proteins 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000002609 medium Substances 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000032696 parturition Effects 0.000 description 2
230000009054 pathological process Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000003405 preventing effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000001185 psoriatic effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
230000035456 regulation of T cell proliferation Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
XABCFXXGZPWJQP-BYPYZUCNSA-N (S)-3-aminoadipic acid Chemical compound OC(=O)C[C@@H](N)CCC(O)=O XABCFXXGZPWJQP-BYPYZUCNSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
MZFYWIHCDIYXOD-UHFFFAOYSA-N 2-aminobutanoic acid;3-aminopropanoic acid Chemical compound NCCC(O)=O.CCC(N)C(O)=O MZFYWIHCDIYXOD-UHFFFAOYSA-N 0.000 description 1
XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 1
SVDVJBWDBYSQLO-UHFFFAOYSA-N 5-(4-hydroxy-3-methoxyphenyl)-5-phenylimidazolidine-2,4-dione Chemical compound C1=C(O)C(OC)=CC(C2(C(NC(=O)N2)=O)C=2C=CC=CC=2)=C1 SVDVJBWDBYSQLO-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 1
YEBZNKPPOHFZJM-BPNCWPANSA-N Ala-Tyr-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O YEBZNKPPOHFZJM-BPNCWPANSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241001136792 Alle Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010060937 Amniotic cavity infection Diseases 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
JSLGXODUIAFWCF-WDSKDSINSA-N Arg-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O JSLGXODUIAFWCF-WDSKDSINSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
208000008158 Chorioamnionitis Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
208000037487 Endotoxemia Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
IHDKKJVBLGXLEL-STQMWFEESA-N Gly-Tyr-Met Chemical compound CSCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(O)=O IHDKKJVBLGXLEL-STQMWFEESA-N 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
229940124084 Interleukin 1 antagonist Drugs 0.000 description 1
108050001109 Interleukin-1 receptor type 1 Proteins 0.000 description 1
102000004125 Interleukin-1alpha Human genes 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
150000008575 L-amino acids Chemical group 0.000 description 1
HFKJBCPRWWGPEY-BQBZGAKWSA-N L-arginyl-L-glutamic acid Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HFKJBCPRWWGPEY-BQBZGAKWSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 1
241000239218 Limulus Species 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
206010051604 Lung transplant rejection Diseases 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
URBJRJKWSUFCKS-AVGNSLFASA-N Lys-Met-Arg Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCCCN)N URBJRJKWSUFCKS-AVGNSLFASA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
CWFYZYQMUDWGTI-GUBZILKMSA-N Met-Arg-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O CWFYZYQMUDWGTI-GUBZILKMSA-N 0.000 description 1
229920001410 Microfiber Polymers 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
108010065338 N-ethylglycine Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
101710171264 Peroxidase 20 Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
102100039832 Ribonuclease pancreatic Human genes 0.000 description 1
101710123428 Ribonuclease pancreatic Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
244000191761 Sida cordifolia Species 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
102100024276 Transcription factor SOX-3 Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000001400 Tryptase Human genes 0.000 description 1
108060005989 Tryptase Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
KKHRWGYHBZORMQ-NHCYSSNCSA-N Val-Arg-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKHRWGYHBZORMQ-NHCYSSNCSA-N 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000003092 anti-cytokine Effects 0.000 description 1
230000002001 anti-metastasis Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000001042 autoregulative effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
239000001273 butane Substances 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000014564 chemokine production Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
230000003297 denaturating effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010252 digital analysis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
108010072542 endotoxin binding proteins Proteins 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
239000003906 humectant Substances 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
230000007233 immunological mechanism Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000017306 interleukin-6 production Effects 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
230000007803 itching Effects 0.000 description 1
201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000003658 microfiber Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007302 negative regulation of cytokine production Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000004493 neutrocyte Anatomy 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
201000009958 panhypopituitarism Diseases 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000007692 polyacrylamide-agarose gel electrophoresis Methods 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000030786 positive chemotaxis Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
230000036647 reaction Effects 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

APAP/P/1998/001295A 1996-01-18 1997-01-16 Synthetic IL-10 analogues. AP883A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/DK1996/000029 WO1997026278A1 (en)	1996-01-18	1996-01-18	Synthetic il-10 analogues
PCT/DK1997/000021 WO1997026279A1 (en)	1996-01-18	1997-01-16	Synthetic il-10 analogues

Publications (2)

Publication Number	Publication Date
AP9801295A0 AP9801295A0 (en)	1998-09-30
AP883A true AP883A (en)	2000-10-25

Family

ID=8155499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1998/001295A AP883A (en)	1996-01-18	1997-01-16	Synthetic IL-10 analogues.

Country Status (14)

Country	Link
US (1)	US6936586B1 (2)
EP (1)	EP0879245A1 (2)
JP (1)	JP2000503652A (2)
KR (1)	KR19990077344A (2)
CN (1)	CN1226899A (2)
AP (1)	AP883A (2)
AR (1)	AR006517A1 (2)
AU (2)	AU4385696A (2)
BR (1)	BR9707036A (2)
CA (1)	CA2243275A1 (2)
PL (1)	PL327928A1 (2)
RU (1)	RU2194054C2 (2)
WO (2)	WO1997026278A1 (2)
ZA (1)	ZA9784B (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4385696A (en) *	1996-01-18	1997-08-11	Christian Gronhoj Larsen	Synthetic il-10 analogues
AU6887096A (en) *	1996-09-11	1998-04-02	Patrick T. Prendergast	Immune direction therapy
EP1021173A1 (en) *	1997-10-10	2000-07-26	Imperial College Innovations Limited	Use of csaid?tm compounds for the management of uterine contractions
DE19851675A1 (de) *	1998-11-10	2000-05-11	Bayer Ag	Menschliche Interleukin-10 Mutantenproteine
WO2000037096A2 (en) *	1998-12-22	2000-06-29	Schering Corporation	Treatment of hepatitis c virus infections with interleukin-10
AU4545301A (en) *	2000-03-14	2001-09-24	Nat Jewish Med & Res Center	Method and composition for treating airway hyperresponsiveness
US20070160576A1 (en) *	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6797722B2 (en) *	2002-05-03	2004-09-28	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
RU2260598C2 (ru) *	2003-10-29	2005-09-20	Российский кардиологический научно-производственный комплекс Министерства здравоохранения РФ	Пептид, обладающий способностью ингибировать миграцию моноцитарных клеток, стимулированную белком мср-1
GB0500643D0 (en) *	2005-01-13	2005-02-23	Renovo Ltd	Medicaments
EP2952522B1 (en)	2007-01-31	2019-10-30	Dana-Farber Cancer Institute, Inc.	Stabilized p53 peptides and uses thereof
AU2008232709C1 (en)	2007-03-28	2015-01-15	President And Fellows Of Harvard College	Stitched polypeptides
AU2014201269B2 (en) *	2008-02-08	2016-09-15	Aileron Therapeutics, Inc.	Therapeutic peptidomimetic macrocycles
KR20100126361A (ko) *	2008-02-08	2010-12-01	에일러론 테라퓨틱스 인코포레이티드	치료용 펩티드유사 거대고리
AR088392A1 (es)	2011-10-18	2014-05-28	Aileron Therapeutics Inc	Macrociclos peptidomimeticos
CA2862038C (en)	2012-02-15	2021-05-25	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
HK1205454A1 (en)	2012-02-15	2015-12-18	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014138429A2 (en)	2013-03-06	2014-09-12	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and use thereof in regulating hif1alpha
WO2016049359A1 (en)	2014-09-24	2016-03-31	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
US10253067B2 (en)	2015-03-20	2019-04-09	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
JP2018528217A (ja)	2015-09-10	2018-09-27	エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
US10610104B2 (en)	2016-12-07	2020-04-07	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
EP3600414A1 (en)	2017-03-30	2020-02-05	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
BR102019007044A2 (pt) *	2019-04-05	2021-12-28	Universidade Federal de Uberlândia	Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0405980A1 (en) *	1989-06-28	1991-01-02	Schering Corporation	Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5624823A (en) *	1991-11-22	1997-04-29	The General Hospital Corporation	DNA encoding procine interleukin-10
EP0629130A1 (en)	1992-03-04	1994-12-21	Schering Corporation	Use of interleukin-10 to suppress graft-vs.-host disease
RU2051922C1 (ru) *	1992-06-19	1996-01-10	Людмила Яковлевна Соловьева	СПОСОБ ВЫДЕЛЕНИЯ РЕКОМБИНАНТНОГО ИНТЕРЛЕЙКИНА - 1β ИЗ БИОМАССЫ МИКРООРГАНИЗМОВ
CA2085291A1 (en)	1992-07-30	1994-01-31	Martin L. Breitman	Novel receptor tyrosine kinase
US5328989A (en) *	1993-03-05	1994-07-12	Schering-Plough	Purification of human interleukin-10 from a cell culture medium
US5446128A (en)	1993-06-18	1995-08-29	The Board Of Trustees Of The University Of Illinois	Alpha-helix mimetics and methods relating thereto
FI960353A7 (fi)	1993-07-26	1996-01-26	Schering Corp	Ihmisen interleukiini-10:n agonistit ja antagonistit
US6159937A (en) *	1994-07-05	2000-12-12	Steeno Research Group A/S	Immunomodulators
US5654276A (en) *	1995-06-07	1997-08-05	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-5 receptor
AU4385696A (en) *	1996-01-18	1997-08-11	Christian Gronhoj Larsen	Synthetic il-10 analogues

1996
- 1996-01-18 AU AU43856/96A patent/AU4385696A/en not_active Abandoned
- 1996-01-18 WO PCT/DK1996/000029 patent/WO1997026278A1/en not_active Ceased
1997
- 1997-01-06 ZA ZA9700084A patent/ZA9784B/xx unknown
- 1997-01-16 JP JP9525609A patent/JP2000503652A/ja not_active Ceased
- 1997-01-16 BR BR9707036-0A patent/BR9707036A/pt not_active Application Discontinuation
- 1997-01-16 AU AU13011/97A patent/AU718476B2/en not_active Ceased
- 1997-01-16 CN CN97193092A patent/CN1226899A/zh active Pending
- 1997-01-16 US US09/101,825 patent/US6936586B1/en not_active Expired - Fee Related
- 1997-01-16 PL PL97327928A patent/PL327928A1/xx unknown
- 1997-01-16 WO PCT/DK1997/000021 patent/WO1997026279A1/en not_active Ceased
- 1997-01-16 KR KR1019980705491A patent/KR19990077344A/ko not_active Ceased
- 1997-01-16 AP APAP/P/1998/001295A patent/AP883A/en active
- 1997-01-16 RU RU98115293/04A patent/RU2194054C2/ru not_active IP Right Cessation
- 1997-01-16 EP EP97900549A patent/EP0879245A1/en not_active Withdrawn
- 1997-01-16 CA CA002243275A patent/CA2243275A1/en not_active Abandoned
- 1997-01-17 AR ARP970100194A patent/AR006517A1/es unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0405980A1 (en) *	1989-06-28	1991-01-02	Schering Corporation	Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Also Published As

Publication number	Publication date
WO1997026278A1 (en)	1997-07-24
CN1226899A (zh)	1999-08-25
AU4385696A (en)	1997-08-11
US6936586B1 (en)	2005-08-30
JP2000503652A (ja)	2000-03-28
CA2243275A1 (en)	1997-07-24
AR006517A1 (es)	1999-09-08
ZA9784B (en)	1997-07-17
AU718476B2 (en)	2000-04-13
BR9707036A (pt)	1999-08-31
EP0879245A1 (en)	1998-11-25
PL327928A1 (en)	1999-01-04
RU2194054C2 (ru)	2002-12-10
AP9801295A0 (en)	1998-09-30
AU1301197A (en)	1997-08-11
KR19990077344A (ko)	1999-10-25
WO1997026279A1 (en)	1997-07-24

Publication	Publication Date	Title
AP883A (en)	2000-10-25	Synthetic IL-10 analogues.
US6168791B1 (en)	2001-01-02	Antibodies that bind immunomodulators
CA2147989C (en)	2002-10-22	Enhancement of xenograft tolerance and porcine cytokines therefor
US20230338473A1 (en)	2023-10-26	Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokinerelease syndrome and cytokine storm associated disorders
HRP970099A2 (en)	1998-04-30	Peptide derivatives
Lillquist et al.	1988	Structure-activity studies of human IL-1 beta with mature and truncated proteins expressed in Escherichia coli.
MXPA98005648A (en)	2001-09-07	Synthetic il-10 analogues
JP2008500289A (ja)	2008-01-10	炎症性気道疾患の治療
EP1250358A1 (en)	2002-10-23	Therapeutic peptides
HK1012416B (en)	2000-12-01	Immunomodulators
Boger et al.	1988	Immunomodulatory approaches to the treatment of inflammation
JP2020505324A5 (2)	2021-02-12
Dionyssopoulou et al.	2000	Synthetic peptides as putative therapeutic agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rβ)
KR100479143B1 (ko)	2005-06-16	T-세포선택적인터루킨-4아고니스트
JP2007512812A (ja)	2007-05-24	羊膜由来ペプチドおよびその使用
EA046995B1 (ru)	2024-05-21	Применение кортексина при цитокиновом шторме